Found 60 matching trials
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN) PHASE1 Subjects on this study have a type of lymph gland cancer called Non-Hodgkin...
Show More Location
Houston Methodist Hospital
Learn More & Join Trial
A Pediatric Trial of Genetically Modified Autologous T Cells Directed Against CD19 for Relapsed CD19+ Acute Lymphoblastic Leukemia PHASE1 Patients with relapsed leukemia often develop resistance to chemotherapy. F...
Show More Status
Active Not Recruiting
Location
Seattle Children's Hospital
Learn More & Join Trial
Sequential CAR-T Cells Targeting BCMA/CD19 in Patients With Relapsed/ Refractory Autoimmune Diseases PHASE1 This is an open, single-arm, clinical study to evaluate the efficacy and sa...
Show More Location
District One Hospital
Learn More & Join Trial
CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR) PHASE1 This study is for patients who have lymphoma or leukemia that has come back...
Show More Status
Active Not Recruiting
Location
Houston Methodist Hospital
Learn More & Join Trial
JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma PHASE1 This phase Ib trial studies whether anti-CD19-chimeric antigen receptor (CA...
Show More Location
Fred Hutch/University of Washington Cancer Consortium
Learn More & Join Trial
Study of KYV-101 Anti-CD19 CAR T Therapy in Adult Dermatomyositis PHASE1 The goal of this clinical trial is to characterize to understand the effect...
Show More Location
Stanford University
Learn More & Join Trial
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2) PHASE1 The purpose of this study is to evaluate the safety, tolerability, efficacy...
Show More Status
Active Not Recruiting
Location
Local Institution - 0011
Learn More & Join Trial
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV) PHASE1 A phase 1/2, open-label, safety and dosing study of autologous CART cells (...
Show More Location
Stanford University, Dept. of Dermatology
Learn More & Join Trial
Clinical Trial of CMD63 Chimeric Antigen Receptor T-cell (CAR T-cell) in Children With Acute Lymphoblastic Leukemia (ALL) PHASE1 A Phase 1 clinical trial to evaluate the safety and early efficacy of Chime...
Show More Learn More & Join Trial
Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma PHASE1 This phase I trial investigates the side effects of brain tumor-specific im...
Show More Status
Active Not Recruiting
Location
City of Hope Medical Center
Learn More & Join Trial